Cellino’s purpose is to build a precision platform that personalizes human cells for all, focusing on Parkinson’s, diabetes and heart disease. Cellino’s platform combines label-free imaging and high-speed laser editing with machine learning to automate cell reprogramming, expansion and differentiation in a closed cassette format, enabling thousands of patient samples to be processed in parallel in a single facility.
The recommended approval of the world's first two therapies derived from induced pluripotent stem cells is a significant move towards improving longevity.
The global population aged over 60 is set to double by 2050. As people live longer, regenerative medicine will be critical to extending healthspan alongside lifespan.
